Anti-Rheumatic Rx
Aurelie Najm
2 years ago
Split dose oral MTX (15/10mg) versus single dose (25mg) in RA RCT 250pts
EULAR good resp
16wks 22 vs 10% (sig)
24wks 37 vs 28% (ns)
50% more addition of 2nd csDMARD in single dose
#ACRBest @RheumNow #ACR23
ABST1583
For more thoughts, have a read https://t.co/urA6X4rY0D 👇🏼
Eric Dein
2 years ago
SMART on MTX
Ab#1583 @RheumNow #ACR23
Single dose MTX 25 mg v Split dose (same day 15/10 mg). FA 5 mg 2x/wk. 16w can add csDMARD
Split 29% vs 22% - EULAR response improve - not signif. Better DAS28
Split: 35% added 2nd csDMARD vs. 54.5% in single dose
No stat diff in sAE
#ACRBest
Robert B Chao, MD
2 years ago
Should Methotrexate be prescribed as split dosing?
Multi-center, RCT of RA pts showed split dosing of 25mg MTX resulted in higher efficacy + reduced need for additional DMARDs, compared to single dose MTX
@RheumNow #ACR23 Abs#1583 https://t.co/zjjnzWUl5E
Dr. Rachel Tate
2 years ago
SMART study #ACR23 Plenary abs #1583: po split-dose MTX (vs single dose) once weekly in RA pts had ^^ efficacy & reduced need for add'l DMARDs. No major AE, but slight increase in frequency of persistent transaminitis in split-dose group. https://t.co/wHzjpSnfuA @rheumnow https://t.co/0hNTMGbt47
sheila
2 years ago
The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX
Reassuring.
. . .
In my practice, pts tolerate MTX split dosing better esp w/⬆️doses
#ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4
Robert B Chao, MD
2 years ago
Does NSAID use = CKD?
Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities.
Long term NSAID use not associated with increased risk of CKD.
@RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc
Dr. Rachel Tate
2 years ago
Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX
Janet Pope
2 years ago
To remind us. Glory be! GLORIA a #RCT in elderly active #RA: MTX+10 mg daily #prednisolone which was better than MTX alone. But more infections and no comparison of inexpensive Rx such as adding #HCQ. Still debated as to benefit vs risk of this strategy @RheumNow #ACR23 @ACRheum https://t.co/slOmESbIOW
Mike Putman EBRheum
2 years ago
Interesting abstract re:dx trajectories, I have a counter-intuitive take
I expect pts w/high dx activity to respond BETTER than pts w/LDA at diagnosis
More autoimmunity + less fibro = higher chance to respond to DMARD?
Anyone else feel that way?
@RheumNow #ACR23 Abstr1426 https://t.co/D6GU7tMcY6
Dr. John Cush RheumNow
2 years ago
Towards Personalised Care in RA
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). #ACR23
https://t.co/SjyfMyPyGw https://t.co/uzG72vKSpd
ACR 2023 is back in San Diego for its annual convergence of thousands of rheumatologists to partake, discover and learn from thousands of abstracts and hundreds of sessions and presentations. It was a big return for the Poster Hall with rows and rows of research, friends, fellows and poster tours. Below are a few of my favorite presentations from the posters, Plenary and oral sessions on day one.
The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
Meral K. El Ramahi, MD MeralElRamahiMD
2 years ago
ABS0155 @ #ACR23
Economic impact of switching from SQ MTX (Rasuvo) from oral MTX in U.S. RA pts?'
➡️ Rasuvo associated with significantly higher all cause total expenditure $4704 predominantly due to higher costs associated tin all cause pharmacy utilization $4,223!
@Rheumnow https://t.co/ry8XxjvHRg
TheDaoIndex KDAO2011
2 years ago
OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH
Meral K. El Ramahi, MD MeralElRamahiMD
2 years ago
ABS0433:
⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective
➡️Retrospect, obs using Medicare data
➡️At least 66 yo old w/ new dx of late-onset RA (LORA)
🚩If no contraindications, start DMARDs early in LORA!
#ACR23 @RheumNow https://t.co/ChalcgtS2O
Poster Hall